Cited by 942Cytokine Signaling Pathways and InteractionsImmunodeficiency and Autoimmune DisordersNF-κB Signaling Pathways

The DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

Open access

O'Shea, John J., Holland, Steven M., Staudt, Louis M.·2013·New England Journal of Medicine

DOI 10.1056/nejmra1202117PMC PMC7604876

Open this paper in CoChat — free account

Abstract

A large number of cytokines signal through the JAK–STAT pathway. Abnormal function of this pathway may lead to a variety of diseases. Targeting the defects in this signaling pathway has already led to treatment advances, and further advances are likely.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmra1202117

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
JAKS AND STATS: Biological Implications
Leonard, W. J., & O’Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,826
Self-citation
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596

Flagged first, then by citations

Show all 101 references

1 of the 101 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

10.1172/JCI0215617 · DOI

Sorted by citations

Items 101–200 of 942

First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers
Fan, Y., Li, S., Ding, X., Yue, J., Jiang, J., Zhao, H., Hao, R., Qiu, W., Liu, K., Li, Y., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5471-1 · Cited by 100
Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma
Lü, L., Zhu, F., Zhang, M., Li, Y., Drennan, A. C., Kimpara, S., Rumball, I., Selzer, C., Cameron, H., Kellicut, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715118115 · Cited by 95
Baricitinib for the Treatment of Alopecia Areata
Freitas, E., Guttman‐Yassky, E., & Torres, T. R. (2023) · Drugs · doi:10.1007/s40265-023-01873-w · Cited by 99
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
Strober, B. E., Buonanno, M., Clark, J. D., Kawabata, T. T., Tan, H., Wolk, R. A., Valdez, H., Langley, R. G. B., Harness, J. A., Menter, A., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12517 · Cited by 99
The value of flavonoids for the human nutrition: Short review and perspectives
Hoensch, H., & Oertel, R. (2015) · Clinical Nutrition Experimental · doi:10.1016/j.yclnex.2015.09.001 · Cited by 100
Autosomal Dominant Hyper-IgE Syndrome in the USIDNET Registry
Gernez, Y., Freeman, A. F., Holland, S. M., Garabedian, E., Patel, N., Puck, J. M., Sullivan, K. E., Akhter, J., Secord, E. A., Chen, K., et al. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.06.041 · Cited by 98
Self-citation
Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase
Hubbard, S. R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00361 · Cited by 112
JAK/STAT inhibitors for the treatment of atopic dermatitis
Rodrigues, M. A., & Torres, T. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1577549 · Cited by 97
From nature to therapy: Luteolin's potential as an immune system modulator in inflammatory disorders
Hussain, M. S., Gupta, G., Goyal, A., Thapa, R., Almalki, W. H., Kazmi, I., Alzarea, S. I., Fuloria, S., Meenakshi, D. U., Jakhmola, V., et al. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23482 · Cited by 99
STAT3 is a central regulator of lymphocyte differentiation and function
Kane, A., Deenick, E. K., Ma, C. S., Cook, M., Uzel, G., & Tangye, S. G. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.015 · Cited by 101
JAK-STAT signaling pathway, immunodeficiency, inflammation, immune dysregulation, and inborn errors of immunity
Samra, S., Bergerson, J., Freeman, A. F., & Turvey, S. E. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.09.020 · Cited by 97
Update on Janus Kinase Antagonists in Inflammatory Bowel Disease
Boland, B. S., Sandborn, W. J., & Chang, J. T. (2014) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2014.05.011 · Cited by 95
STAT5B deficiency: Impacts on human growth and immunity
Hwa, V. (2015) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2015.12.006 · Cited by 96
Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
Ma, C., Lee, J. K., Mitra, A. R., Teriaky, A., Choudhary, D., Nguyen, T. M., Casteele, N. V., Khanna, R., Panaccione, R., Feagan, B. G., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15297 · Cited by 96
Cyclin-Dependent Kinases as Coregulators of Inflammatory Gene Expression
Schmitz, M. L., & Kracht, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.004 · Cited by 94
Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study
Schmieder, G. J., Draelos, Z. D., Pariser, D. M., Banfield, C. R., Cox, L. A., Hodge, M. R., Kieras, E., Parsons‐Rich, D., Menon, S., Salganik, M. P., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16004 · Cited by 93
The emerging role of signal transducer and activator of transcription 3 in cerebral ischemic and hemorrhagic stroke
Liang, Z., Wu, G., Fan, C., Xu, J., Jiang, S., Yan, X., Di, S., Ma, Z., Hu, W., & Yang, Y. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.11.001 · Cited by 92
Drosophila as a model for the two myeloid blood cell systems in vertebrates
Gold, K. S., & Brückner, K. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.06.002 · Cited by 99
Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases
Gadina, M., Gazaniga, N. R., Vian, L., & Furumoto, Y. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.06.006 · Cited by 92
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
Hosseini, A., Gharibi, T., Marofi, F., Javadian, M., Babaloo, Z., & Baradaran, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29593 · Cited by 94
Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival
Qin, S., Li, Q., Xu, J., Liang, J., Cheng, Y., Fan, Y., Jiang, J., Ye, H., Tao, H., Li, L., et al. (2020) · Cancer Science · doi:10.1111/cas.14641 · Cited by 97
miR-375 inhibits Helicobacter pylori-induced gastric carcinogenesis by blocking JAK2–STAT3 signaling
Miao, L., Liu, K., Xie, M., Xing, Y., & Xi, T. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1550-y · Cited by 90
STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy
Spitzner, M., Ebner, R., Wolff, H. A., Ghadimi, Β. M., Wienands, J., & Grade, M. (2014) · Cancers · doi:10.3390/cancers6041986 · Cited by 93
Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells
Bell, C. J. M., Sun, Y. S., Nowak, U. M., Clark, J., Howlett, S., Pekalski, M. L., Yang, X., Ast, O., Waldhauer, I., Freimoser–Grundschober, A., et al. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.10.002 · Cited by 86
Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas
Jiang, Y., Redmond, D., Nie, K., Eng, K. W., Clozel, T., Martin, P., Tan, L. H. C., Melnick, A. M., Tam, W., & Elemento, O. (2014) · Genome biology · doi:10.1186/s13059-014-0432-0 · Cited by 99
JAK inhibition in inflammatory bowel disease
Olivera, P. A., Danese, S., & Peyrin‐Biroulet, L. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1291342 · Cited by 89
Shwachman-Diamond Syndrome: Molecular Mechanisms and Current Perspectives
Bezzerri, V., & Cipolli, M. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0368-2 · Cited by 88
STAT3 Activation and Oncogenesis in Lymphoma
Zhu, F., Wang, K. B., & Rui, L. (2019) · Cancers · doi:10.3390/cancers12010019 · Cited by 92
Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
von Manstein, V., Yang, C., Richter, D. E., Delis, N., Vafaizadeh, V., & Groner, B. (2014) · Current Signal Transduction Therapy · doi:10.2174/1574362409666140206221931 · Cited by 88
TLR4-mediated inflammation is a key pathogenic event leading to kidney damage and fibrosis in cyclosporine nephrotoxicity
González-Guerrero, C., Cannata-Ortiz, P., Guerri, C., Egido, J., Ortiz, A., & Ramos, A. M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1830-8 · Cited by 82
JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors
Irey, E. A., Lassiter, C. M., Brady, N. J., Chuntova, P., Wang, Y., Knutson, T. P., Henzler, C. M., Chaffee, T. S., Vogel, R. I., Nelson, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816410116 · Cited by 84
The Dysregulation of Inflammatory Pathways Triggered by Copper Exposure
Deng, H., Zhu, S., Yang, H., Cui, H., Guo, H., Deng, J., Ren, Z., Geng, Y., Ouyang, P., Xu, Z., et al. (2022) · Biological Trace Element Research · doi:10.1007/s12011-022-03171-0 · Cited by 90
Fatal combined immunodeficiency associated with heterozygous mutation in STAT1
Sharfe, N., Nahum, A., Newell, A., Dadi, H., Ngan, B., Pereira, S. L., Herbrick, J.-A., & Roifman, C. M. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.09.032 · Cited by 85
Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis
Genovese, M. C., Smolen, J. S., Takeuchi, T., Burmester, G. R., Brinker, D. R., Rooney, T. P., Zhong, J., Mo, D., Saifan, C., Cardoso, A., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30032-1 · Cited by 85
Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019
Setyawan, J., Azimi, N. A., Strand, V., Yarur, A. J., & Fridman, M. (2021) · Drug Safety · doi:10.1007/s40264-021-01082-y · Cited by 85
Mendelian Genetics of Human Susceptibility to Fungal InfectionPreprint
Lionakis, M. S., Netea, M. G., & Holland, S. M. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019638 · Cited by 88
Self-citation
Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies
Bohra, C., Sokol, L., & Dalia, S. M. (2017) · Cancer Control · doi:10.1177/1073274817729901 · Cited by 84
JAK–STAT Targeting Offers Novel Therapeutic Opportunities in Sepsis
Clère-Jehl, R., Mariotte, A., Meziani, F., Bahram, S., Georgel, P., & Helms, J. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.06.007 · Cited by 86
Pharmacological Effects of Polyphenol Phytochemicals on the JAK-STAT Signaling Pathway
Yin, Q., Wang, L., Yu, H., Chen, D., Zhu, W., & Sun, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.716672 · Cited by 86
IL-6 Trans–Signaling Links Inflammation with Angiogenesis in the Peritoneal Membrane
Catar, R. A., Witowski, J., Zhu, N., Lücht, C., Soria, A. D., Fernandez, J. U., Chen, L., Jones, S. A., Fielding, C. A., Rudolf, A. H., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015101169 · Cited by 85
Kinase inhibition, competitive binding and proteasomal degradation: resolving the molecular function of the suppressor of cytokine signaling ( SOCS ) proteins
Linossi, E. M., & Nicholson, S. E. (2015) · Immunological Reviews · doi:10.1111/imr.12305 · Cited by 86
The Jakinibs in systemic lupus erythematosus: progress and prospects
Mok, C. C. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1551358 · Cited by 84
The role of the JAK-STAT pathway in neural stem cells, neural progenitor cells and reactive astrocytes after spinal cord injury
Wang, T., Yuan, W., Liu, Y., Zhang, Y., Wang, Z., Zhou, X., Ning, G., Zhang, L., YAO, L., Feng, S., et al. (2014) · Biomedical Reports · doi:10.3892/br.2014.401 · Cited by 84
A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Pemmaraju, N., Kantarjian, H. M., Kadia, T. M., Cortes, J. E., Borthakur, G. M., Newberry, K. J., Garcia‐Manero, G., Ravandi, F., Jabbour, E. J., DellaSala, S. E., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.08.003 · Cited by 84
Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment
Kim, B., Yi, E. H., & Ye, S. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0795-8 · Cited by 81
The pathogenesis and potential therapeutic targets in sepsis
Zhang, W., Jiang, H., Wu, G., Huang, P., Wang, H., An, H., Liu, S., & Zhang, W. (2023) · MedComm · doi:10.1002/mco2.418 · Cited by 85
Janus kinase inhibitors in dermatology: Part II. A comprehensive review
Chapman, S., Gold, L. S., & Lim, H. W. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.06.873 · Cited by 79
Signal Transducer and Activator of Transcription 3 Control of Human T and B Cell Responses
Deenick, E. K., Pelham, S. J., Kane, A., & Ma, C. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00168 · Cited by 77
Identity crisis of Th17 cells: many forms, many functions, many questions
Sundrud, M. S., & Trivigno, C. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.021 · Cited by 77
STAT1 signaling shields T cells from NK cell-mediated cytotoxicity
Kang, Y. H., Biswas, A., Field, M., & Snapper, S. B. (2019) · Nature Communications · doi:10.1038/s41467-019-08743-8 · Cited by 76
Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More
Schreiner, P., Neurath, M. F., Ng, S. C., El-Omar, E. M., Sharara, A. I., Kobayashi, T., Hisamatsu, T., Hibi∥, T., & Rogler, G. (2019) · Inflammatory Intestinal Diseases · doi:10.1159/000500721 · Cited by 79
Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica
Camellino, D., Giusti, A., Girasole, G., Bianchi, G., & Dejaco, C. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00705-5 · Cited by 76
IFNγ-induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapy
Beziaud, L., Young, C. M., Alonso, A. M., Norkin, M., Minafra, A. R., & Huelsken, J. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.05.007 · Cited by 83
Targeting oncogenic transcription factors: therapeutic implications of endogenous STAT inhibitors
Heppler, L. N., & Frank, D. A. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.10.004 · Cited by 74
Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases
Yuan, S., Wang, L., Zhang, H., Xu, F., Zhou, X., Yu, L., Sun, J., Chen, J., Ying, H., Xu, X., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104488 · Cited by 73
Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
Biggioggero, M., Becciolini, A., Crotti, C., & Agape, E. (2019) · Drugs in Context · doi:10.7573/dic.212595 · Cited by 72
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
Song, Y., Malpica, L., Cai, Q., Zhao, W., Zhou, K., Wu, J., Zhang, H., Mehta–Shah, N., Ding, K., Liu, Y. Z., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00589-2 · Cited by 72
Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma
Rui, L., Drennan, A. C., Ceribelli, M., Zhu, F., Wright, G. W., Huang, D. W., Xiao, W., Li, Y., Grindle, K. M., Lü, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610970113 · Cited by 73
Self-citation
Curcumin as an Adjuvant to Cancer Immunotherapy
Paul, S., & Sa, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675923 · Cited by 74
STAT3 Activation in Circulating Monocytes Contributes to Neovascular Age-Related Macular Degeneration
Chen, M., Lechner, J., Zhao, J., Tóth, L., Hogg, R. E., Silvestri, G., Kissenpfennig, A., Chakravarthy, U., & Xu, H. (2016) · Current Molecular Medicine · doi:10.2174/1566524016666160324130031 · Cited by 71
Systemic lupus erythematosus: pathogenesis and targeted therapy
Su, X., Yu, H. M., Lei, Q., Chen, X., Tong, Y., Zhang, Z., Yang, W., Guo, Y., & Lin, L. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00217-8 · Cited by 84
Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis
Tabarroki, A., Lindner, D. J., Visconte, V., Zhang, L., Rogers, H. J., Parker, Y., Duong, H. K., Lichtin, A. E., Kalaycio, M. E., Sekeres, M. A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.5 · Cited by 70
Signal transducer and activator of transcription 3
Forbes, L. R., Milner, J., & Haddad, É. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000206 · Cited by 69
STAT mutations as program switchers: turning primary immunodeficiencies into autoimmune diseases
Lorenzini, T., Dotta, L., Giacomelli, M., Vairo, D., & Badolato, R. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0516-237rr · Cited by 77
JAK-STAT in Lipid Metabolism of Adipocytes
Xu, D., Yin, C., Wang, S., & Xiao, Y. (2013) · JAK-STAT · doi:10.4161/jkst.27203 · Cited by 69
Discovery of (2 R )‑ N ‑[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]‑1 H ‑indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor
Su, Q., Banks, E., Bebernitz, G. A., Bell, K., Borenstein, C. F., Chen, H., Chuaqui, C. E., Deng, N., Ferguson, A. D., Kawatkar, S. P., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01392 · Cited by 70
COVID-19 and lung cancer: risks, mechanisms and treatment interactions
Addeo, A., Obéid, M., & Friedlaender, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000892 · Cited by 71
STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological NKG2Dhi CD8+ T cell dysregulation and accumulation
Masle‐Farquhar, E., Jackson, K., Peters, T. J., Al‐Eryani, G., Singh, M., Payne, K. J., Rao, G., Avery, D. T., Apps, G., Kingham, J., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.11.001 · Cited by 68
The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals
Koblansky, A. A., Truax, A. D., Liu, R., Montgomery, S. A., Ding, S., Wilson, J. E., Brickey, W. J., Mühlbauer, M., McFadden, R.-M. T., Hu, P., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.064 · Cited by 73
Rebuilding Pluripotency from Primordial Germ Cells
Leitch, H. G., Nichols, J., Humphreys, P. D., Mulas, C., Martello, G., Lee, C. Y., Jones, K., Surani, M. A., & Smith, A. G. (2013) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.03.004 · Cited by 67
Retracted: Long noncoding RNA SNHG16 contributes to the development of bladder cancer via regulating miR‐98/STAT3/Wnt/β‐catenin pathway axis
Feng, F., Chen, A., Huang, J., Xia, Q., Chen, Y., & Jin, X. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27257 · Cited by 67
Retracted
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
Kotyla, P. J., Engelmann, M., Giemza-Stokłosa, J., Wnuk, B. R., & Islam, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052449 · Cited by 70
Cytokine Signaling in Tumor Progression
Lee, M., & Rhee, I. (2017) · Immune Network · doi:10.4110/in.2017.17.4.214 · Cited by 67
JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
Moura, R. A., & Fonseca, J. E. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.607725 · Cited by 67
Curcumin inhibits the cancer‑associated fibroblast‑derived chemoresistance of gastric cancer through the suppression of the JAK/STAT3 signaling pathway
Ham, I., Wang, L., Lee, D., Woo, J., Kim, T. I., Jeong, H. Y., Oh, H. J., Choi, K. S., Kim, T., & Hur, H. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5375 · Cited by 66
Inflammation, cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis
Zhou, S., & Chen, X. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86396 · Cited by 76
Beyond Good and Evil: Molecular Mechanisms of Type I and III IFN Functions
Dowling, J. W., & Forero, A. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100707 · Cited by 73
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
Genovese, M. C., Kremer, J. M., Kartman, C. E., Schlichting, D. E., Xie, L., Carmack, T., Pantojas, C., Bursón, J. S., Tony, H., Macias, W. L., et al. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/kex489 · Cited by 65
JAK1: Number one in the family; number one in inflammation?
Spinelli, F. R., Colbert, R. A., & Gadina, M. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keab024 · Cited by 64
Developmental neurotoxicity and immunotoxicity induced by graphene oxide in zebrafish embryos
Yang, X., Yang, Q., Zheng, G., Han, S., Zhao, F., Hu, Q., & Fu, Z. (2018) · Environmental Toxicology · doi:10.1002/tox.22695 · Cited by 65
STAT1 and STAT3 mutations: important lessons for clinical immunologists
Olbrich, P., & Freeman, A. F. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1531704 · Cited by 66
Overexpression of microRNA-155 increases IL-21 mediated STAT3 signaling and IL-21 production in systemic lupus erythematosus
Rasmussen, T. K., Andersen, T., Bak, R. O., Yiu, G., Sørensen, C. M., Stengaard‐Pedersen, K., Mikkelsen, J. G., Utz, P. J., Holm, C. K., & Deleuran, B. W. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0660-z · Cited by 64
Therapies in Canine Atopic Dermatitis
Santoro, D. (2018) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2018.08.002 · Cited by 63
TYK2: An Upstream Kinase of STATs in Cancer
Wöss, K., Simonović, N., Strobl, B., Macho‐Maschler, S., & Müller, M. M. (2019) · Cancers · doi:10.3390/cancers11111728 · Cited by 67
AQP1 modulates tendon stem/progenitor cells senescence during tendon aging
Chen, M., Li, Y., Xiao, L., Dai, G.-C., Lu, P., Wang, Y., & Rui, Y. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2386-3 · Cited by 62
Hispidulin: A novel natural compound with therapeutic potential against human cancers
Ashaq, A., Maqbool, M. F., Maryam, A., Khan, M. N., Shakir, H. A., Irfan, M. I., Qazi, J. I., Li, Y., & Ma, T. (2020) · Phytotherapy Research · doi:10.1002/ptr.6862 · Cited by 65
Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy
Winthrop, K. L., Bingham, C. O., Komocsar, W. J., Bradley, J., Issa, M., Klar, R., & Kartman, C. E. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1883-1 · Cited by 61
Nuclear receptors in inflammation control: Repression by GR and beyond
Chinenov, Y. V., Gupte, R., & Rogatsky, I. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.04.006 · Cited by 61
microRNA control of interferons and interferon induced anti-viral activity
Sedger, L. M. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.07.009 · Cited by 66
Mass cytometry identifies a distinct monocyte cytokine signature shared by clinically heterogeneous pediatric SLE patients
O’Gorman, W. E., Kong, D. S. H., Balboni, I., Rudra, P., Bolen, C. R., Ghosh, D., Davis, M. M., Nolan, G. P., & Hsieh, E. W. Y. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.03.010 · Cited by 62
JAK2/STAT3 as a new potential target to manage neurodegenerative diseases: An interactive review
Panda, S. P., Kesharwani, A., Datta, S., Prasanth, D., Panda, S. K., & Guru, A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176490 · Cited by 61
Tyrosine kinase 2 – Surveillant of tumours and bona fide oncogene
Leitner, N. R., Witalisz‐Siepracka, A., Strobl, B., & Müller, M. M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.10.015 · Cited by 59
Restoring the Balance between Pro-Inflammatory and Anti-Inflammatory Cytokines in the Treatment of Rheumatoid Arthritis: New Insights from Animal Models
Markovics, A., Rosenthal, K. S., Mikecz, K., Carambula, R. E., Ciemielewski, J. C., & Zimmerman, D. H. (2021) · Biomedicines · doi:10.3390/biomedicines10010044 · Cited by 59
G‐CSF / GM‐CSF ‐induced hematopoietic dysregulation in the progression of solid tumors
He, K., Liu, X., Hoffman, R. D., Shi, R.-Z., Lv, G., & Gao, J. (2022) · FEBS Open Bio · doi:10.1002/2211-5463.13445 · Cited by 60
Exploring the JAK/STAT Signaling Pathway in Hepatocellular Carcinoma: Unraveling Signaling Complexity and Therapeutic Implications
Park, H., Lee, S.-H., Lee, J., Moon, H., & Ro, S. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813764 · Cited by 63
Current perspectives on microglia-neuron communication in the central nervous system: Direct and indirect modes of interaction
Hu, Y., & Tao, W. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.01.006 · Cited by 64
Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity
Mertens, C., Haripal, B., Klinge, S., & Darnell, J. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515876112 · Cited by 59
Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients
Martinović, K. M., Babović, N. L., Džodić, R. R., Jurišić, V., Tanić, N., & Konjević, G. M. (2014) · Melanoma Research · doi:10.1097/cmr.0000000000000072 · Cited by 60
Inhibiting STAT5 by the BET Bromodomain Inhibitor JQ1 Disrupts Human Dendritic Cell Maturation
Toniolo, P. A., Liu, S., Yeh, J., Moraes‐Vieira, P. M., Walker, S. R., Vafaizadeh, V., Barbuto, J. A. M., & Frank, D. A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401635 · Cited by 57
Stem Cell-Based Therapies for Inflammatory Bowel Disease
Zhang, H., Yuan, S., Meng, H., Hou, X.-T., Li, J., Xue, J.-C., Li, Y., Wang, Q., Nan, J., Jin, X., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158494 · Cited by 57

Authors: O'Shea, J. J., Holland, S. M., & Staudt, L. M.
Affiliations: National Institute of Allergy and Infectious Diseases (US)
National Institutes of Health (US)
ORCID: Holland, Steven M.
Staudt, Louis M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-01-10
Volume: 368
Issue: 2
Pages: 161-170
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra1202117
PMC: PMC7604876
OpenAlex: W2040002852
Cited by: 927
References: 101
Citations by year: 2026: 47 · 2025: 61 · 2024: 64 · 2023: 76 · 2022: 79 · 2021: 91 · 2020: 78 · 2019: 60 · 2018: 44 · 2017: 70 · 2016: 66 · 2015: 69 · 2014: 67 · 2013: 52
FWCI: 8.98
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (Z01SC004024)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (ZIAAR041106)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
Keywords: JAK/STAT signaling, cytokine signaling, immunodeficiency, cancer, immune regulation, JAK inhibitors, STAT inhibitors, targeted therapy
MeSH terms: Hematologic Diseases, Humans, Immunologic Deficiency Syndromes, Mutation, Neoplasms, Signal Transduction, Cytokines, STAT Transcription Factors, Janus Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks